Multi-Omics Study Identifies ADAMTS8 and IL6R as Potential Aortic Aneurysm Therapeutic Targets
Researchers have identified ADAMTS8 and IL6R as potential therapeutic targets for aortic aneurysm following an integrated multi-omics study.
The findings, published in Artery Research, suggest these genes could guide future drug development for the condition.
To pinpoint these targets, investigators conducted a two-sample Mendelian randomisation analysis using 5,900 potentially druggable genes. The team evaluated genetic variants associated with gene expression in both arterial tissues and blood, according to the European Medical Journal.
The study employed complementary approaches including protein quantitative trait locus analyses, heterogeneity testing, and Bayesian co-localisation to confirm the candidates. Genetically predicted ADAMTS8 expression appeared linked to lower diastolic blood pressure but higher systolic blood pressure, while IL6R expression correlated with a reduced risk of allergies.
Mediation analyses indicated that coronary atherosclerosis accounted for approximately 10% of the association between IL6R and aortic aneurysm, while high-density lipoprotein levels accounted for 2.5%.
Exploratory gene–compound analysis further identified four compounds—cyclopenthiazide, primaquine, decitabine, and progesterone—that showed associations with both identified targets.
The researchers cautioned that these drug associations serve as preliminary hypotheses rather than clinical evidence of effectiveness. While spatial transcriptomic analysis pointed toward potential tissue-specific signals in the lung, adipose tissue, and connective tissue, these results did not maintain statistical significance after corrections for multiple testing.
Single-cell RNA sequencing revealed that IL6R expression was numerically higher in aneurysm tissues compared to control samples, though the difference did not reach statistical significance. ADAMTS8 expression remained low across the cellular populations examined.
The authors said that the study remains computational and requires further experimental and clinical validation to establish biological relevance, safety, and therapeutic application. Future research is needed to determine if these genetic targets can eventually be translated into treatments for aortic aneurysm.